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Creutzfeldt-Jakob disease (CJD) is a fatal rare neurode-
generative protein misfolding disease with a yearly inci-
dence ranging from one to two per million. Most cases are
of sporadic origin and the clinical phenotype, age at onset
and disease duration are determined by the polymorphism
at codon 129 of the prion protein gene (PRNP) and the
prion protein type (PrP
Sc) on western blot [1]. 10–15% of
CJD cases are of genetic origin, caused by an autosomal
dominant mutation in the PRNP at the short arm of chro-
mosome 20 (genetic Creutzfeldt-Jakob disease—gCJD). So
far, more than 30 mutations in the PRNP are known.
The worldwide most common mutations are E200K (A
to G transition at codon 200 PRNP with substitution of
lysine (K) for glutamate (E)) and V210I (G to A transition
at codon 210 PRNP with substitution of isoleucin (I) for
valine (V)) [2]. For the E200K mutation a cluster of cohorts
were identiﬁed in Libyan Jews, Chile and Slovakia [3]. The
clinical spectrum of these patients is reported similar to
sCJD, except for the age at disease onset (average 10 years
earlier disease onset in E200K) [2, 4]. The codon 129
PRNP genotype was identiﬁed to inﬂuence disease onset
and duration (shorter mean disease duration in methionine-
homozygous patients (3.7 ± 2.0 months) than in methio-
nine/valine-heterozygous patients (7.84 ± 7.3 months))
[4]. About the V210I mutation several case reports were
published, but actually no clear comprehensive clinical
picture exists. In general, the mean age at onset ranged at
50 years, the mean disease duration at 4 months in patients
with the V210I mutation [2, 5]. Comprehensive data from
the literature about both mutations suggest that the majority
of cases feature a similar phenotype like sporadic CJD in
absence of a positive family history of prion diseases. In
our study, we analyzed the clinical phenotype and results
of diagnostic tests in patients with gCJD E200K and V210I
and compared them to sCJD control groups matched by
age, gender and PRNP 129 codon genotype (for both
mutations separate sCJD control groups in the same
patients number). We then compared the results between
the mutations and the control group. By means of statistical
relevance the PrP type was not considered in this study, as
it was not available in most cases. All patient data analyzed
in this study derived from the German CJD surveillance
unit since it was established in 1993. The E200K group
comprised 23 patients with a median age at onset of
63 years (range 29–75 years) and median disease duration
of 9 months (range 2–19 months), thereof 15 female and 8
male patients (Table 1). In 47% of these patients at least
one more E200K mutation affected relative was identiﬁed.
Twelve patients were homozygous for methionine, eleven
heterozygous for methionine/valine, whereas in eight of the
heterozygous patients the mutation was linked to the
methionine allele (E200K–M) and in three patients it was
linked to the valine allele (E200K–V). The mean age at
disease onset did not differ between homozygous and
heterozygous patients (MM 65 ± 10 years, MV
62 ± 12 years, p = 0.728), but disease duration varied
signiﬁcantly (MM 6 ± 3 months, MV 12 ± 5 months,
p B 0.001). When compared to sCJD, no signiﬁcant dif-
ferences in those parameters were detected. There was a
signiﬁcant difference between the E200K–M (65 years)
and E200K–V (61 years) connected mutation carrier in age
at onset (p = 0.025), however no difference in disease
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DOI 10.1007/s10654-012-9660-3duration (E200K–M 6.5 months, E200K–V 11.3 months;
p = 0.808). The E200K–V patients were signiﬁcantly
younger at disease onset than the heterozygous sCJD
patients (E200K–V 51 years, MV sCJD 64 years;
p = 0.036), whereby no differences between E200K–M
and methionine homozygous sCJD patients were detect-
able. No divergence of age at onset and disease duration
existed between cases with a positive family history and
cases without a positive family history of the E200K
mutation. The V210I cohort of 16 patients (MM = 13,
MV = 3, all linked to methionine), thereof 9 female and 7
male without positive family history of prion diseases in
any case (Table 1). The mean age at onset was 63 years
(range 45–80 years), the mean disease duration 6 months
(range 1–20 months). Homozygous and heterozygous
patients had a similar average age at onset (MM
61 ± 11 years, MV 55 ± 8 years, p = 0.238) and disease
duration (MM 5 ± 5 months, MV 2 ± 0.4 months,
p = 0.181). Frequent clinical symptoms in both mutations
at disease onset were part of a prodromal phase (vertigo,
personality change and headache) followed by dementia
and ataxia. All sensory disturbances as well as half of all
psychiatric features in both mutations appeared at disease
onset and during the disease all typical symptoms of CJD
were presented (Table 2). The mutation carriers presented
a variety of clinical symptoms similiar to the sCJD control
Table 1 Demographic data of the E200K and V210I PRNP mutation carrier
Demographic data E200K V210I
Total
n = 23
MM
n = 12
MV
n = 11
Total
n = 16
MM
n = 13
MV
n = 3
Male:female 1:1.8 1:1 4.5:1 1:1 1.6:1 1:2
Age at onset (years) 63 (29–75) 65 (43–73) 62 (29–75) 63 (45–80) 61 (52–80) 55 (48–64)
Disease duration (months) 9 (2–19) 6 (2–11) 12 (5–19) 6 (1–20) 5 (1–20) 2 (2–3)
Table 2 Results of the diagnosing tests and frequency of clinical
symptoms in E200K mutation carrier and V210I mutation carrier as
well as the sCJD control groups (different sCJD controls matched by
age, gender and codon 129 PRNP genotype separately for both
mutations with the same number of patients)
Diagnostic tests E200K sCJD V210I sCJD
14-3-3
MM (%) 100 100 100 100
MV (%) 82 82 100 67
Median tau [pg/ml]
MM 8628 11472 7628 10716
MV 4172 2319 7686 2348
EEG
MM (%) 27 42 46 50
MV (%) 27 10 33 50
MRI
MM (%) 88 90 100 80
MV (%) 90 100 100 100
Clinical signs (%) Disease onset During disease Disease onset During disease
E200K sCJD E200K sCJD V210I sCJD V210I sCJD
Prodromal phase 74 83 74 83 75 81 75 81
Dementia 61 48 87 87 69 69 88 100
Cerebellar signs 52 78 100 100 63 75 100 100
Myoclonic jerks 9 4 65 87 25 19 88 88
Pyramidal signs 35 17 83 57 13 31 38 75
Extrapyramidal signs 13 9 70 52 31 6 81 75
Psychiatric features 30 48 70 70 13 25 31 63
Sensory disturbances 30 13 30 13 19 6 38 6
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123group. By analysing symptom appearance (onset) we could
not verify any differences between the E200K patients and
the tightly matched sCJD control group. However, between
homozygous and heterozygous E200K patients myoclonic
jerks (p = 0.007), pyramidal signs (p = 0.015), extrapy-
ramidal symptoms (p = 0.003) and psychiatric features
(p = 0.003) appeared signiﬁcantly later in disease course
in heterozygous patients. Compared to V210I psychiatric
features occured later in sCJD (p = 0.008), homozygous
V210I mutation carrier developed cerebellar signs later
than heterozygous patients (p = 0.019). The E200K and
V210I mutation distinguished by the fact that dementia
(p = 0.019), pyramidal signs (p = 0.041), extrapyramidal
signs (p = 0.004) and psychiatric features (p\0.001)
appeared later in the E200K mutation, whereby both
groups were not matched by age, gender or PRNP poly-
morphism. The results of the diagnosing tests revealed a
positive CSF 14-3-3 protein in 91% of the E200K mutation
carrier (MM = 100%, MV = 82%) and in 100% of the
V210I mutation carrier. The median level of tau protein in
E200K mutation ranged at 6400 pg/ml (range 1300–24638
pg/ml). Codon 129 PRNP homozygous mutation carrier had
a trend towards lower tau levels than heterozygous patients
(MM = 8628 pg/ml; MV = 4172 pg/ml; p = 0.071). Tau
values differed substantially in homozygous and heterozy-
gous sCJD patients (MM = 11472; MV = 2319 pg/ml;
p = 0.004). In the E200K mutation the tau and the age at
onset presented with an inverse correlation whereby we
observed lower tau values in older patients (r =- 0.555,
p = 0.007). In the V210I mutation the median tau protein
levels ranged at 7640 pg/ml (MM = 7628 pg/ml, MV =
7686 pg/ml, p = 0.991) with no differences between PRNP
codon 129 homozygous and heterozygous patients. In sCJD
controls a signiﬁcant difference between homozygous and
heterozygous patients was similarly presented (MM =
8762 pg/ml, MV = 1529 pg/ml; p B 0.001). The sCJD
control group and patients with gCJD presented no differ-
ences between frequency of positive CSF 14-3-3 protein or
values oftau protein. 27%of the E200K patientsand 44%of
the V210I mutation carrier demonstrated typical periodic
sharp wave complexes (PSWC) on EEG. On MRI, 89% of
the E200K mutation carrier and 95% of the sCJD control
patients met the current MRI criteria regarding to hyperin-
tensities in basal ganglia and/or cortical areas (Table 2). In
60% of the E200K mutation carrier we found white matter
lesions (WML), whereby patients with WML were signiﬁ-
cantlyolderincontrasttothepatientswithoutWML(median
age WML = 63 years; median age no WML = 58 years;
p B 0.05).InthesCJDcontrolgroupthefrequencyofWML
was even higher with presence in 90%. We did not detect a
statistically signiﬁcant difference in the age of patients with
WML as compared to those without WML. In V210I
mutation all of the patients presented with a positive MRI
scan for CJD (sCJD 83%), we also found WML (30%), but
less frequently than in the E200K mutation. Statistical
analyses revealed no variances between the mutations and
sCJD control groups in results of EEG and MRI.
In conclusion, we demonstrated that patients with the
E200K and the V210I mutation exhibited a similar clinical
syndrome as sporadic CJD patients and presented similar
ﬁndings in the diagnosing tests, given that they were
matched to age, gender and codon 129 PRNP polymor-
phism. In contrast to the V210I mutation carrier, the
E200K mutation clinical symptoms of dementia, pyramidal
signs, extrapyramidal signs and psychiatric features
appeared later in disease course what could be a distinctive
feature. An aspect of our patients was that we did not ﬁnd
strategic differences between PRNP codon 129 polymor-
phism in each group, whereby this parameter represents
one of the strongest susceptibility factor of phenotypic
variability in sCJD. Another interesting result was the
detection of a high rate of WML, whereby the reasons for
white matter involvement in CJD have not been well
explained yet. Summarizing, in absence of a positive
family history and no obvious indications to distinguish the
origin of the CJD, only wide genetic testing of all CJD
patients allows an accurate diagnosis of a genetic disorder.
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